Ayden Scheim


Affiliate Scientist


Please note Dr. Scheim will not be taking any summer students.

Dr. Scheim is an Affiliate Scientist with the Centre on Drug Policy Evaluation, Li Ka Shing Knowledge Institute.

His primary appointment is as an Assistant Professor of Epidemiology in the Drexel University Dornsife School of Public Health in Philadelphia. He is also an Adjunct Assistant Professor in Epidemiology and Biostatistics at Western University. Dr. Scheim investigates the impacts of social, policy, and healthcare environments on the health of populations facing stigma. In particular, his research program involves community-engaged research with transgender populations and structurally vulnerable people who use drugs.

Recent Publications

  1. Logie, CH, van der Merwe, LLA, Scheim, A. Measuring sex, gender, and sexual orientation: one step to health equity. Lancet. 2022; :. doi: 10.1016/S0140-6736(22)01425-8. PubMed PMID:35908554 .
  2. Rammohan, I, Bouck, Z, Fusigboye, S, Bowles, J, McDonald, K, Maghsoudi, N et al.. Drug checking use and interest among people who inject drugs in Toronto, Canada. Int J Drug Policy. 2022;107 :103781. doi: 10.1016/j.drugpo.2022.103781. PubMed PMID:35803177 .
  3. Kia, H, Rutherford, L, Jackson, R, Grigorovich, A, Ricote, CL, Scheim, AI et al.. Impacts of COVID-19 on trans and non-binary people in Canada: a qualitative analysis of responses to a national survey. BMC Public Health. 2022;22 (1):1284. doi: 10.1186/s12889-022-13684-x. PubMed PMID:35780082 PubMed Central PMC9250198.
  4. Earnshaw, VA, Jonathon Rendina, H, Bauer, GR, Bonett, S, Bowleg, L, Carter, J et al.. Methods in HIV-Related Intersectional Stigma Research: Core Elements and Opportunities. Am J Public Health. 2022;112 (S4):S413-S419. doi: 10.2105/AJPH.2021.306710. PubMed PMID:35763749 PubMed Central PMC9241464.
  5. Dang, M, Scheim, AI, Teti, M, Quinn, KG, Zarwell, M, Petroll, AE et al.. Barriers and Facilitators to HIV Pre-Exposure Prophylaxis Uptake, Adherence, and Persistence Among Transgender Populations in the United States: A Systematic Review. AIDS Patient Care STDS. 2022;36 (6):236-248. doi: 10.1089/apc.2021.0236. PubMed PMID:35687813 .
  6. Lazor, T, Blondal, E, Scheim, A, Cubillos, P, Werb, D, Milloy, MJ et al.. Measurement of public health impacts of cannabis legalization in Canada to reflect policy maker priorities: A rapid scoping review of instruments and content domains. Drug Alcohol Depend. 2022;236 :109463. doi: 10.1016/j.drugalcdep.2022.109463. PubMed PMID:35594643 .
  7. Mitra, S, Kolla, G, Bardwell, G, Wang, R, Sniderman, R, Mason, K et al.. Requiring help injecting among people who inject drugs in Toronto, Canada: Characterising the need to address sociodemographic disparities and substance-use specific patterns. Drug Alcohol Rev. 2022;41 (5):1062-1070. doi: 10.1111/dar.13473. PubMed PMID:35577755 .
  8. Ward, KM, Scheim, A, Wang, J, Cocchiaro, B, Singley, K, Roth, AM et al.. Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program. Drug Alcohol Depend Rep. 2022;3 :100055. doi: 10.1016/j.dadr.2022.100055. PubMed PMID:35497489 PubMed Central PMC9040407.
  9. Bouck, Z, Scheim, AI, Gomes, T, Ling, V, Caudarella, A, Werb, D et al.. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions. Int J Drug Policy. 2022;104 :103680. doi: 10.1016/j.drugpo.2022.103680. PubMed PMID:35447476 PubMed Central PMC9005368.
  10. Werb, D, Scheim, AI, Soipe, A, Aeby, S, Rammohan, I, Fischer, B et al.. Health harms of non-medical prescription opioid use: A systematic review. Drug Alcohol Rev. 2022;41 (4):941-952. doi: 10.1111/dar.13441. PubMed PMID:35437841 PubMed Central PMC9064965.
Search PubMed

Affiliations & Other Activities

Postdoctoral Fellow, University of California San Diego